Celsus Therapeutics (NASDAQ:CLTX) on 17 June has received approval from the Israeli Ministry of Health to conduct a Phase II trial of MRX-6 cream 2% in pediatric patients with atopic dermatitis. Celsus Therapeutics PLC (ADR) (NASDAQ:CLTX) weekly performance is 11.50%. On last trading day company shares ended up $6.69. Celsus Therapeutics PLC (ADR) (NASDAQ:CLTX) distance from 50-day simple moving average (SMA50) is 18.35%.
China Biologic Products, Inc. (NASDAQ:CBPO) held its 2014 Annual Meeting of Stockholders (the “Annual Meeting”) on Friday, June 20, 2014. Proxies for the Annual Meeting were solicited pursuant to the Company’s amended proxy statement filed on May 19, 2014 with the Securities and Exchange Commission under Section 14(a) of the Securities Exchange Act of 1934 (the “Amended Proxy Statement”). China Biologic Products Inc. (NASDAQ:CBPO) shares advanced 2.09% in last trading session and ended the day on $43.44. CBPO gross Margin is 67.60% and its return on assets is 18.60%.China Biologic Products Inc. (NASDAQ:CBPO) quarterly performance is 34.03%.
Veracyte Inc. (NASDAQ:VCYT) CEO Bonnie H. Anderson unloaded 4,000 shares of the company’s stock in a transaction dated Monday, June 23rd. The shares were sold at an average price of $16.45, for a total value of $65,800.00. Veracyte Inc. (NASDAQ:VCYT) shares moved up 3.38% in last trading session and was closed at $16.82, while trading in range of $16.01 – $17.45. Veracyte Inc. (NASDAQ:VCYT) year to date (YTD) performance is 16.00%.
Ohr Pharmaceutical, Inc. (NASDAQ:OHRP), a research and development company with a primary focus in ophthalmology, announced that it will host a conference call and webcast on Tuesday, June 24th to discuss Squalamine interim Phase II data in wet age-related macular degeneration (“wet-AMD”). OHR Pharmaceutical Inc. (NASDAQ:OHRP) ended the last trading day at $11.40. Company weekly volatility is calculated as 7.89% and price to cash ratio as 76.93.OHR Pharmaceutical Inc. (NASDAQ:OHRP) showed a positive weekly performance of 27.95%.